Molnupiravir (EIDD-2801) CAS 2349386-89-4 COVID-19 API Didara Giga
Ipese Iṣowo Molnupiravir ati Awọn agbedemeji ibatan pẹlu Didara Giga
Uridine CAS 58-96-8
Cytidine CAS 65-46-3
Molnupiravir N-1 CAS 2346620-55-9
Molnupiravir (EIDD-2801) CAS 2349386-89-4
| Orukọ Kemikali | Molnupiravir (EIDD-2801) |
| Awọn itumọ ọrọ sisọ | MK-4482;β-D-N4-Hydroxycytidine-5'-isopropyl ester;((2R,3S,4R,5R) -3,4-dihydroxy-5-((E) -4- (hydroxyimino) -2-oxo-3,4-dihydropyrimidin-1 (2H) -yl) tetrahydrofuran-2 -yl) methyl isobutyrate |
| Nọmba CAS | 2349386-89-4 |
| NỌMBA CAT | RF-API97 |
| Iṣura Ipo | Ninu Iṣura, Iwọn iṣelọpọ Ti o to Awọn ọgọọgọrun Kilogram |
| Fọọmu Molecular | C13H19N3O7 |
| Òṣuwọn Molikula | 329.31 |
| Solubility | Tiotuka ni DMSO |
| Brand | Ruifu Kemikali |
| Nkan | Awọn pato |
| Ifarahan | Funfun to Pa-White Powder |
| Idanimọ IR | Ayẹwo julọ.Oniranran ni ibamu si ti boṣewa itọkasi |
| HPLC idanimọ | Akoko idaduro ti oke pataki ti ojutu ayẹwo ni ibamu si ti ojutu boṣewa |
| Awọn nkan ti o jọmọ | |
| Aimọ́ A | ≤0.15% |
| Aimọ́ B | ≤0.15% |
| Eyikeyi Aisọye Aimọ | ≤0.15% |
| Lapapọ Awọn aimọ ti a ko ni pato | ≤0.30% |
| Lapapọ Awọn Aimọ | ≤0.50% |
| Awọn ohun elo ti o ku | |
| N-Heptane | ≤5000ppm |
| Ethanol | ≤5000ppm |
| Isopropyl acetate | ≤5000ppm |
| Acetonitrile | ≤410ppm |
| Methylene dichloride | ≤600ppm |
| Acetone | ≤5000ppm |
| Isopropanol | ≤5000ppm |
| Akoonu Omi (KF) | ≤0.50% |
| Aloku lori Iginisonu | ≤0.10% |
| Yiyi opitika | -7.5° si -9.5° (C=0.5, Methanol) |
| Awọn irin Heavy | ≤10ppm |
| Mimọ / Analysis Ọna | ≥99.5% (230nm) |
| Aseyori / Analysis Ọna | 98.0% ~ 102.0% (HPLC lori ipilẹ gbigbẹ) |
| Igbesi aye selifu | 24 osu |
| Igbeyewo Standard | Standard Enterprise |
| Lilo | API, Molnupiravir (EIDD-2801) COVID-19 Inhibitor |
Package: Igo, apo apamọwọ Aluminiomu, ilu paali, 25kg / Drum, tabi gẹgẹbi ibeere alabara.
Ipò Ìpamọ́:Fipamọ sinu awọn apoti ti a fi edidi ni itura ati ibi gbigbẹ;Dabobo lati ina, ọrinrin ati kokoro infestation.
Molnupiravir (EIDD-2801, MK-4482) jẹ arosọ bioavailable ẹnu ti ribonucleoside afọwọṣe β-d-N4-hydroxycytidine (NHC; EIDD-1931) pẹlu iṣẹ ṣiṣe antiviral ti o gbooro si SARS-CoV-2, MERS-CoV, SARS-CoV, ati aṣoju okunfa ti COVID-19.Molnupiravir ti wa ni tita labẹ orukọ iyasọtọ Lagevrio ati ni gbogbogbo bi emorivir.Molnupiravir ti han lati mu iṣẹ ẹdọforo dara, dinku pipadanu iwuwo ara ati dinku iye ọlọjẹ ninu ẹdọforo.Ni afikun si iṣẹ ṣiṣe lodi si awọn coronaviruses, Molnupiravir, ninu awọn ijinlẹ yàrá, ti ṣe afihan iṣẹ ṣiṣe lodi si akoko ati aarun ayọkẹlẹ ẹiyẹ, ọlọjẹ syncytial atẹgun, ọlọjẹ chikungunya, ọlọjẹ Ebola, ọlọjẹ equine encephalitis Venezuelan, ati ọlọjẹ equine encephalitis Ila-oorun.Molnupiravir ti ni idagbasoke ni akọkọ lati tọju aarun ayọkẹlẹ ni Ile-ẹkọ giga Emory nipasẹ ile-iṣẹ innovation oogun ti ile-ẹkọ giga, Drug Innovation Ventures at Emory (DRIVE), ṣugbọn a royin pe o ti kọ silẹ fun awọn ifiyesi iyipada.Lẹhinna o gba nipasẹ ile-iṣẹ orisun Miami Ridgeback Biotherapeutics, eyiti o ṣe ajọṣepọ nigbamii pẹlu Merck & Co. lati ṣe idagbasoke oogun naa siwaju.Molnupiravir jẹ ifọwọsi fun lilo iṣoogun ni United Kingdom ni Oṣu kọkanla ọdun 2021.
